Clinical trials: Respiratory Symptoms
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
To compare the bronchodilator efficacy and safety of tiotropium inhalation capsules (18 µg once daily) and Atrovent® MDI (2 puffs of 20µg q.i.d.) among Filipino patients with COPD
- Trial name
- NCT02172469
- Testing
- Tiotropium inhalation powder capsule, Ipratropium Bromide Metered Dose Inhaler
- Volunteers
- 215 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to obtain additional data on efficacy and safety of Rengalin in the treatment of cough in patients with stable obstructive pulmonary disease
- Trial name
- NCT03159091
- Testing
- Rengalin
- Where
- 18 sites in Russia
- Volunteers
- 238 people
- Sponsor
- Materia Medica Holding
Lung Cancer, Breast Cancer
Improving Cancer Outcomes Through Personalized Care Planning and Symptom Management.
This Study is a case control Study conducted with 100 patients with a solid tumor cancer diagnosis (lung, breast, or gynecologic cancer).
- Conditions
- Lung Cancer, Breast Cancer, Gynecologic Cancer
- Trial name
- NCT04772118
- Testing
- Carevive PROmpt™
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Carevive Systems, Inc.
Chronic Bronchitis, Chronic Obstructive Pulmonary Disease
A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)
The purpose of this study was to evaluate the effect of ION-827359 on forced expiratory volume in 1 second (FEV1) in participants with mild to moderate COPD with CB.
- Trial name
- NCT04441788
- Testing
- ION-827359
- Where
- 15 sites in Czechia, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Solid Tumor
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in…
- Trial name
- NCT04931823
- Testing
- CPO-100
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Tinnitus, Hearing Disorders
Evaluation of Potential Causes of Nap Modulated Tinnitus
The proposed research is a non-interventional study made to evaluate different measurements on 1 group of participants, before and after taking a nap, aiming to potentially guide future investigations on nap-modulated tinnitus to…
- Conditions
- Tinnitus, Hearing Disorders, Ear Diseases, Otorhinolaryngologic Diseases
- Trial name
- TinniNap (NCT05467059)
- Testing
- Napping
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Robin Guillard EIRL
Brain Metastases, Lung Cancer
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of 2B3-101 both as single agent and in combination with trastuzumab.
- Conditions
- Brain Metastases, Lung Cancer, Breast Cancer, Melanoma
- Trial name
- NCT01386580
- Testing
- 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 84 people
- Sponsor
- BBB-Therapeutics B.V.
Advanced Emphysema
A Dose Ranging Study of the Aeris Polymeric Lung Volume Reduction (PLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema
This is a multi-center, open-label, non-controlled Pilot Study. Approximately 24 patients will be assigned to one of 3 treatment groups (8 patients each group).
- Trial name
- NCT00884962
- Testing
- Polymeric Lung Volume Reduction System (PLVR)
- Where
- 6 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Aeris Therapeutics
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to demonstrate the efficacy of inhaled treprostinil compared to placebo in improving exercise ability as measured by change from baseline in 6-Minute Walk Distance (6MWD) following 12 weeks…
- Trial name
- PERFECT (NCT03496623)
- Testing
- Inhaled treprostinil solution
- Where
- 76 sites in United States, Argentina and 2 more
- Volunteers
- 188 people
- Sponsor
- United Therapeutics
Refractory Chronic Cough and Unexplained Chronic Cough
A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough
This is a randomized placebo-controlled, parallel-arm study to determine the safety and efficacy of SC0032 in participants with RCC
- Trial name
- SensoryCloud (NCT07690059)
- Testing
- SC0032
- Where
- 3 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Sensory Cloud, Inc.
Chronic Obstructive Pulmonary Disease
Observational Study to Evaluate Health Status of Chronic Obstructive Pulmonary Disease (COPD) Patients in Response to Real-life Treatments in Thailand
The purpose of this study is to evaluate health status of uncontrolled Chronic Obstructive Pulmonary Disease (COPD) patients in response to treatments in clinical practice.
- Trial name
- NCT01169727
- Where
- 20 sites in Thailand
- Volunteers
- 684 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.
The objective of the study was to evaluate the degree of improvement in lung function in patients with chronic obstructive pulmonary disease (COPD) after treatment with tiotropium inhalation capsules compared to salmeterol…
- Trial name
- NCT00274560
- Testing
- Tiotropium, Salmeterol
- Where
- 50 sites in United States, Finland and 6 more
- Volunteers
- 653 people
- Sponsor
- Boehringer Ingelheim
Severe Eosinophilic Asthma, Nasal Polyps
RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
The purpose of this observational study is to describe the population of patients with SEA + NP who have been prescribed FASENRA and assess available clinical outcomes for both NP and asthma.
- Trial name
- RANS (NCT05180357)
- Testing
- FASENRA(benralizumab)
- Where
- 45 sites in United States, France and 4 more
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients
This study will evaluate the pharmacokinetics, pharmacodynamics and safety of multiple doses of the NVA237 in mild and moderate COPD patients .
- Trial name
- NCT00545311
- Testing
- NVA237
- Where
- 4 sites in Denmark, Germany
- Volunteers
- 40 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks
The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticanse propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to…
- Trial name
- NCT01772134
- Testing
- Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg
- Where
- 73 sites in United States, Canada and 2 more
- Volunteers
- 617 people
- Sponsor
- GlaxoSmithKline
Pulmonary Fibrosis
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers and the Effect of Itraconazole on CHF10073 Exposure
The objective of this study is to assess the safety and tolerability of single ascending doses of inhaled CHF10073 (Part 1 of the study) and multiple ascending doses of CHF10073 (Part 2 of the study).
- Trial name
- NCT06746064
- Testing
- CHF10073 (Part 1 - SAD), CHF10073 (Part 2 - MAD), CHF10073 (Part 3)
- Where
- Belgium
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease (COPD)
Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
This is a 52-week treatment, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of once-daily QVA149 (indacaterol and NVA237 ([glycopyrronium bromide]) using tiotropium as…
- Trial name
- NCT01285492
- Testing
- QVA149, Tiotropium
- Where
- 35 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD
The purpose of this 24 week study is to evaluate the spirometric lung function effect (trough FEV1) of Umeclidinium/Vilanterol 62.5/25 once daily compared to Tiotropium 18 mcg once daily along with safety assessments in subjects…
- Trial name
- NCT01777334
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Tiotropium 18 mcg
- Where
- 70 sites in United States, Argentina and 7 more
- Volunteers
- 905 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444.
- Trial name
- COPD (NCT01328444)
- Testing
- GSK 573719 +GW642444 125/25, GSK573719 + GW642444 62.5/25, GSK 573719 125
- Where
- 31 sites in United States, Bulgaria and 4 more
- Volunteers
- 349 people
- Sponsor
- GlaxoSmithKline
Alpha 1-Antitrypsin Deficiency
Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin…
- Trial name
- SEQUOIA (NCT03945292)
- Testing
- Fazisiran Injection
- Where
- 21 sites in United States, Germany and 4 more
- Volunteers
- 40 people
- Sponsor
- Arrowhead Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.